biostudies-literatureHe HXNational Science &amp; Technology Major Project7650-7664https://www.ebi.ac.uk/biostudies/studies/S-EPMC8559475biostudies-literatureUnknown10(21)<h4>Purpose</h4>Some studies have indicated that using 500 mg/m² rituximab combined with CHOP-14 may be beneficial for elderly men but not women with diffuse large B-cell lymphoma (DLBCL). The purpose of this study was to investigate the potential benefit of escalated doses of rituximab with CHOP-21 as the first-line treatment in male patients with DLBCL.<h4>Methods</h4>We performed a retrospective cohort study to analyze the survival benefit of rituximab 500 mg/m² plus the CHOP-21 regimen (Escalated-R-CHOP-21) as the first-line treatment compared with using rituximab 375 mg/m² plus the CHOP-21 regimen (Standard-R-CHOP-21) in men with DLBCL. We used propensity score matching to maximize the balance of the observed covariables. The primary endpoints of this Cancer medicineThe beneficial effect of Escalated-R-CHOP-21 for the treatment of diffuse large B-cell lymphoma in elderly male patients: A propensity-matched cohort study.PMC85594752017ZX09304021Huang CBai BLi JBHe YXHuang HLi ZMHuang HQCai QQPing LQHe HXRong QXJiang WQGao YMao JYWang XXfalseThe beneficial effect of Escalated-R-CHOP-21 for the treatment of diffuse large B-cell lymphoma in elderly male patients: A propensity-matched cohort study.<h4>Purpose</h4>Some studies have indicated that using 500 mg/m² rituximab combined with CHOP-14 may be beneficial for elderly men but not women with diffuse large B-cell lymphoma (DLBCL). The purpose of this study was to investigate the potential benefit of escalated doses of rituximab with CHOP-21 as the first-line treatment in male patients with DLBCL.<h4>Methods</h4>We performed a retrospective cohort study to analyze the survival benefit of rituximab 500 mg/m² plus the CHOP-21 regimen (Escalated-R-CHOP-21) as the first-line treatment compared with using rituximab 375 mg/m² plus the CHOP-21 regimen (Standard-R-CHOP-21) in men with DLBCL. We used propensity score matching to maximize the balance of the observed covariables. The primary endpoints of this 2021-01-01T00:00:00Z2021 Nov2025-05-29T21:34:15.374Z2025-05-29T21:34:15.374ZS-EPMC85594753458102310.1002/cam4.4296